MYCN and neuroblastoma: With the development of the risk classification system introduced by International Neuroblastoma Risk Group (INRG), patients are divided into different risk categories according to their clinical markers such as age, tumor stage, and histology as well as genetic markers such as MYCN amplification and arm-level alterations of chromosomes (6).